secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001816590-25-000149
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways accelerates COMP360 TRD launch by 9-12 months; Q3 net loss $137.7M
--------------------------------------------------------------------------------

- Accelerating commercialization readiness by 9-12 months after positive FDA meeting on NDA strategy including potential rolling submission.
- COMP006 9-week data and COMP005 26-week data expected Q1 2026; COMP006 26-week data expected early Q3 2026.
- Cash $185.9M as of Sept 30, 2025; full-year 2025 net cash used in operations expected $120M-$145M.
- Q3 2025 net loss $137.7M ($1.44/share) includes $101.3M non-cash loss on warrant fair value adjustment.
- R&D expenses $27.3M in Q3 2025 vs $32.9M in Q3 2024, down due to discontinued discovery programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/0001816590-25-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/cmps-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001816590-25-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer